This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Feeney, M. Articles by Bast, R. C. Search for Related Content PubMed PubMed Citation Articles by Feeney, M. Articles by Bast, R. C., Jr.

Elimination of Leukemic Cells from Rat Bone Marrow Using Antibody and Complement¹

Divisions of Tumor Immunology [M. F., R. C. B.], Medical Oncology [R. C. B.], Radiation Biology [J. S. G.], and Gynecologic Oncology [R. C. K.], Sidney Farber Cancer Institute, and the Departments of Medicine [R. C. B.], Radiation Therapy [J. S. G.], and Obstetrics and Gynecology [R. C. K.], Harvard Medical School, Boston, Massachusetts 02115

An animal model has been developed that utilizes antibody and complement to eliminate a transplantable cloned line of Wistar/Furth acute nonlymphocytic leukemia (Cl-3) from syngeneic Wistar/Furth bone marrow. The Cl-3 leukemia grows progressively from an i.v. inoculum of 10¹ to 10² cells. Antiserum has been raised in rabbits following multiple injections of Cl-3. Using optimal concentrations of absorbed antibody and complement, approximately 3 logs of tumor could be destroyed in vitro, judged by the number of cells required to produce progressive growth in vivo. Similar incubation with antibody and complement did not affect the ability of Wistar-Further marrow to reconstitute rats that had received lethal total-body irradiation (950 R). Each of the 33 irradiated rats that received mixtures of 10⁴ Cl-3 and 1.6 x 10⁸ nucleated bone marrow cells succumbed to leukemia within 65 days, whereas 16 of 33 rats (48%) receiving similar inocula that had been treated with antibody and complement survived > 180 days without evidence of tumor growth. Repeated treatment of contaminated marrow with antibody and complement following removal of mature granulocytes and erythrocytes on density gradients permitted elimination of 10⁵ Cl-3.

¹ This investigation was supported in part by NIH Biomedical Research Support Grant 2-507-RR05526-17 and by Grant 1-R01-CA 28740-01, awarded by the National Cancer Institute, Department of Health and Human Services.

² Scholar of the Leukemia Society of America.

Received 8/14/80. Accepted 6/ 2/81.